Post-operative Concurrent Chemo-radiotherapy Versus Post-operative Radiotherapy for Cancer of the Head and Neck

PHASE3CompletedINTERVENTIONAL
Enrollment

321

Participants

Timeline

Start Date

April 30, 2005

Primary Completion Date

March 31, 2016

Study Completion Date

March 31, 2016

Conditions
Skin Cancer
Interventions
DRUG

Carboplatin

Carboplatin will commence with a dose calculated to target an AUC of 2.0. A maximum of 6 doses of weekly Carboplatin will be given. Carboplatin will be administered intravenously over 20-30 minutes prior to radiation therapy.

RADIATION

Radiotherapy

60 Gy OR 66Gy in 2Gy/fraction 5days/week

Trial Locations (21)

1001

Auckland Hospital, Auckland

1871

Liverpool Hospital, Liverpool

2050

Royal Prince Alfred Hospital, Sydney

2065

Royal North Shore Hospital, St Leonards

2145

Westmead Hospital, Wentworthville

2298

Calvary Mater Newcastle, Newcastle

2500

Illawarra Cancer Care Centre, Wollongong

2650

Riverina Cancer Centre, Wagga Wagga

3002

Peter MacCallum Cancer Centre, East Melbourne

3004

William Buckland Radiotherapy Centre, The Alfred, Melbourne

3200

Waikato Hospital, Hamilton

3220

Andrew Love Cancer Care Centre, Geelong Hospital, Geelong

4029

Royal Brisbane Hospital, Herston

4101

Mater QRI, South Brisbane

4102

Princess Alexandra Hospital, Brisbane

4224

Genesis Cancer Care (previously Premion), Tugun

4350

St Andrew's Toowoomba Hospital, Toowoomba

4710

Christchurch Hospital, Christchurch

4810

North Queensland Oncology Service, Townsville

5000

Royal Adelaide Hospital, Adelaide

Unknown

Palmerston North Hospital, Palmerston North

All Listed Sponsors
collaborator

Princess Alexandra Hospital, Brisbane, Australia

OTHER

collaborator

The Royal Australian and New Zealand College of Radiologists

OTHER

lead

Trans Tasman Radiation Oncology Group

OTHER

NCT00193895 - Post-operative Concurrent Chemo-radiotherapy Versus Post-operative Radiotherapy for Cancer of the Head and Neck | Biotech Hunter | Biotech Hunter